With a long strong heritage in immunology on the strength of blockbuster brands like Remicade (infliximab), Stelara (ustekinumab) and Tremfya (guselkumab), Johnson & Johnson is looking to continue its leadership in categories like psoriasis, psoriatic arthritis and inflammatory bowel disease with the development of new oral medicines.
J&J In Immunology: 'We Plan To Lead The Orals Market'
Johnson & Johnson’s historical strength in immunology will form the foundation of a renewed push in the field, with novel candidates for indications such as psoriasis, arthritis and inflammatory bowel disease.
More from Immunological
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.